Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis.
Select Content Type
Clinical Guidelines
Authored By
Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, Holl RW
Authored On
Interests
Urology & Nephrology
Internal/Family Medicine
Speciality
Urology & Nephrology
Internal/Family Medicine
Book Detail
volume
22
ISSN
1471-2369
Publication Date
Actions
Download in App
Event Data
{"article_title":"Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis.","author":"\"Bramlage, Peter , Lanzinger, Stefanie , Tittel, Sascha R , Hess, Eva , Fahrner, Simon , Heyer, Christoph H J , Friebe, Mathias , Buschmann, Ivo , Danne, Thomas , Seufert, Jochen , Holl, Reinhard W\"","journal_title":"BMC nephrology","issn":"1471-2369 ; Electronic","isbn":"","publication_date":"20210519","volume":"22","issue":"1","first_page":"184","page_count":"","accession_number":"34011313","doi":"10.1186\/s12882-021-02394-y","publisher":"BioMed Central","doctype":"Journal Article; Research Support","subjects":"Diabetes ","interest_area":["Urology & Nephrology"," Internal\/Family Medicine"],"abstract":"Recent European Society of Cardiology (ESC)\/European Association for the Study of Diabetes (EASD) guidelines provide recommendations for detecting and treating chronic kidney disease (CKD) in diabetic patients. We compared clinical practice with guidelines to determine areas for improvement.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34011313&authtype=shib&custid=ns346513","isPdfLink":true,"isSAML":false,"additionalInfo":{"Authored_By":"Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, Holl RW","Journal_Info":"Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE","Publication_Type":"Journal Article; Research Support, Non-U.S. Gov't","Published_Date":"2021-05-19","Source":"BMC nephrology [BMC Nephrol] 2021 May 19; Vol. 22 (1), pp. 184. Date of Electronic Publication: 2021 May 19.","Languages":"English","Electronic_ISSN":"1471-2369","MeSH_Terms":"Guideline Adherence*, Diabetes Mellitus, Type 1\/*drug therapy , Diabetes Mellitus, Type 2\/*drug therapy , Diabetic Nephropathies\/*prevention & control , Hypoglycemic Agents\/*therapeutic use, Adult ; Aged ; Antihypertensive Agents\/therapeutic use ; Diabetes Mellitus, Type 1\/blood ; Diabetes Mellitus, Type 2\/blood ; Diabetic Nephropathies\/diagnosis ; Female ; Glycated Hemoglobin\/analysis ; Humans ; Hypertension\/drug therapy ; Male ; Middle Aged ; Practice Guidelines as Topic ; Registries ; Renal Insufficiency, Chronic\/prevention & control ; Sodium-Glucose Transporter 2 Inhibitors\/therapeutic use","Subjects":"Adult, Aged, Antihypertensive Agents therapeutic use, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Diabetic Nephropathies diagnosis, Female, Glycated Hemoglobin analysis, Humans, Hypertension drug therapy, Male, Middle Aged, Practice Guidelines as Topic, Registries, Renal Insufficiency, Chronic prevention & control, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies prevention & control, Guideline Adherence, Hypoglycemic Agents therapeutic use","Title_Abbreviations":"BMC nephrology","Volume":"22"},"header":{"DbId":"mdl","DbLabel":"MEDLINE Ultimate","An":"34011313","RelevancyScore":"854","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"854.050170898438"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34011313&authtype=shib&custid=ns346513&group=main&profile=eds","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=mdl&AN=34011313&authtype=shib&custid=ns346513&group=main&profile=eds"}
["Bramlage P, Lanzinger S, Tittel SR, Hess E, Fahrner S, Heyer CHJ, Friebe M, Buschmann I, Danne T, Seufert J, Holl RW","Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE","Journal Article; Research Support, Non-U.S. Gov't","2021-05-19","BMC nephrology [BMC Nephrol] 2021 May 19; Vol. 22 (1), pp. 184. Date of Electronic Publication: 2021 May 19.","English","1471-2369","Guideline Adherence*, Diabetes Mellitus, Type 1\/*drug therapy , Diabetes Mellitus, Type 2\/*drug therapy , Diabetic Nephropathies\/*prevention & control , Hypoglycemic Agents\/*therapeutic use, Adult ; Aged ; Antihypertensive Agents\/therapeutic use ; Diabetes Mellitus, Type 1\/blood ; Diabetes Mellitus, Type 2\/blood ; Diabetic Nephropathies\/diagnosis ; Female ; Glycated Hemoglobin\/analysis ; Humans ; Hypertension\/drug therapy ; Male ; Middle Aged ; Practice Guidelines as Topic ; Registries ; Renal Insufficiency, Chronic\/prevention & control ; Sodium-Glucose Transporter 2 Inhibitors\/therapeutic use","Adult, Aged, Antihypertensive Agents therapeutic use, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Diabetic Nephropathies diagnosis, Female, Glycated Hemoglobin analysis, Humans, Hypertension drug therapy, Male, Middle Aged, Practice Guidelines as Topic, Registries, Renal Insufficiency, Chronic prevention & control, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Diabetic Nephropathies prevention & control, Guideline Adherence, Hypoglycemic Agents therapeutic use","BMC nephrology","22"]
Description
Background: Recent European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines provide recommendations for detecting and treating chronic kidney disease (CKD) in diabetic patients. We compared clinical practice with guidelines to determine areas for improvement.<br />Methods: German database analysis of 675,628 patients with type 1 or type 2 diabetes, with 134,395 included in this analysis. Data were compared with ESC/EASD recommendations.<br />Results: This analysis included 17,649 and 116,747 patients with type 1 and type 2 diabetes, respectively. The analysis showed that 44.1 and 49.1 % patients with type 1 and type 2 diabetes, respectively, were annually screened for CKD. Despite anti-diabetic treatment, only 27.2 % patients with type 1 and 43.5 % patients with type 2 achieved a target HbA1c of < 7.0 %. Use of sodium-glucose transport protein 2 inhibitors (1.5 % type 1/8.7 % type 2 diabetes) and glucagon-like peptide-1 receptor agonists (0.6 % type 1/5.2 % type 2 diabetes) was limited. Hypertension was controlled according to guidelines in 41.1 and 67.7 % patients aged 18-65 years with type 1 and 2 diabetes, respectively, (62.4 vs. 68.4 % in patients > 65 years). Renin angiotensin aldosterone inhibitors were used in 24.0 and 40.9 % patients with type 1 diabetes (micro- vs. macroalbuminuria) and 39.9 and 47.7 %, respectively, in type 2 diabetes.<br />Conclusions: Data indicate there is room for improvement in caring for diabetic patients with respect to renal disease diagnosis and treatment. While specific and potentially clinically justified reasons for non-compliance exist, the data may serve well for a critical appraisal of clinical practice decisions.
